peptidylprolyl isomerase A pseudogene 90Genealiases: []
Q-omics provides the consensus-scored PPIAP90 profile across patient tissues and cancer cell-line models. PPIAP90 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PPIAP90 is differentially expressed in 7, with the highest sampling consensus in CHOL. Additionally, PPIAP90 RNA expression shows 12,291 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight LUAD, CHOL, and LAML as cancer lineages where PPIAP90 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP90 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP90 survival associations across molecular data types. PPIAP90 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP90 RNA expression–survival associations across cancer types. High PPIAP90 expression shows unfavorable associations in UCEC, KIRC, UVM and COAD, but favorable associations in LUAD and UCS. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PPIAP90 RNA expression.
This table summarizes PPIAP90 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP90. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP90 shows lower tumor expression in UCEC, ESCA and LUSC and higher tumor expression in CHOL, LUAD and THCA. The CHOL box plot shows higher PPIAP90 RNA expression in tumor versus normal tissue (log2 FC = +0.356, t-test p = .019).
This table shows molecular features associated with PPIAP90 in patient tissues and cancer cell lines. In patient samples, PPIAP90 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
